Johnson & Johnson Gestione
Criteri Gestione verificati 2/4
Johnson & Johnson Il CEO è Joaquin Duato, nominato in Jan2022, e ha un mandato di 4.42 anni. la retribuzione annua totale è $ 32.76M, composta da 4.9% di stipendio e 95.1% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.015% delle azioni della società, per un valore di $ 85.81M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 6.5 anni e 6 anni.
Informazioni chiave
Joaquin Duato
Amministratore delegato
US$32.8m
Compenso totale
| Percentuale dello stipendio del CEO | 4.88% |
| Mandato del CEO | 4.4yrs |
| Proprietà del CEO | 0.01% |
| Durata media del management | 6.5yrs |
| Durata media del Consiglio di amministrazione | 6yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Aggiornamento della narrazione • Jun 04
JNJ: Future Drug Cycle Momentum Is Expected To Drive Returns
Analysts have nudged their price targets for Johnson & Johnson higher, with recent revisions clustering in the mid to high $260s and up to $280, as they point to strong new drug momentum and product cycle strength as key drivers supporting slightly higher revenue growth expectations and a rich future P/E framework. Analyst Commentary Recent research remains broadly constructive on Johnson & Johnson, with several bullish analysts citing product cycle momentum, new drug contributions, and a supportive P/E setup.Seeking Alpha • May 23
Johnson & Johnson: A Dividend King, But Priced Appropriately, Big Conference Slate
Summary Johnson & Johnson is rated Hold, trading near intrinsic value with limited upside based on a 20x multiple and $12 normalized EPS. Q1 results showed 10% sales growth and a $450M revenue beat, with management raising FY 2026 guidance and extending the dividend growth streak to 64 years. JNJ faces headwinds from biosimilar and generic competition, MedTech challenges, and commercial sluggishness, but maintains strong FCF yield and a robust product pipeline. Technicals are mixed but lean bullish, with $235 as near-term resistance and investors advised to monitor upcoming conference commentary and sector momentum. Read the full article on Seeking AlphaAggiornamento della narrazione • May 14
JNJ: Future Drug Cycle And Legal Outcomes Are Expected To Shape Returns
Analysts have nudged their average price target on Johnson & Johnson slightly higher to about $253, citing stronger momentum from new drugs like Icotyde and Inlexzo, along with increased confidence in the pipeline highlighted in recent research updates. Analyst Commentary Recent research on Johnson & Johnson clusters around the same core themes you are seeing in price target moves, with most commentary tied to execution on new products, confidence in the pipeline, and how the company is positioned within healthcare more broadly.Aggiornamento della narrazione • Apr 24
JNJ: Fair Outlook Balances Healthcare Demand With Legal And Portfolio Reshaping Risks
The analyst price target for Johnson & Johnson has been raised by about $11 to $252.42. Analysts point to stronger modeled revenue growth, higher projected profit margins, and a slightly richer future P/E multiple as key drivers of the update.Aggiornamento della narrazione • Apr 09
JNJ: Fair Outlook Sees Healthcare Demand And Legal Outcomes Shape Resilience
Analysts have made a modest upward adjustment to the fair value estimate for Johnson & Johnson, supported by a series of recent price target increases that reflect their updated views on the product pipeline, medical technology trends, and the broader appeal of healthcare stocks. Analyst Commentary Recent research updates on Johnson & Johnson show a cluster of higher price targets and fresh coverage that investors are watching closely.Aggiornamento della narrazione • Mar 25
JNJ: Fair Outlook Balances Legal Overhang With Core Healthcare Resilience
Analysts lifted the Johnson & Johnson fair value estimate by about $3.79 to $241.08, citing higher assumed revenue growth, slightly adjusted profit margin expectations, and a modestly higher future P/E multiple supported by recent upward price target revisions across the Street. Analyst Commentary Recent Street research on Johnson & Johnson has leaned more constructive, with a series of higher price targets clustered above the latest fair value estimate.
Nuova narrazione • Mar 18
Oncology Reliance And MedTech Execution Will Threaten Long Term Earnings Stability
Catalysts About Johnson & Johnson Johnson & Johnson is a global health care company focused on pharmaceuticals and medical technology across Oncology, Immunology, Neuroscience, Cardiovascular, Surgery and Vision. What are the underlying business or industry changes driving this perspective?Aggiornamento della narrazione • Mar 11
JNJ: Pharma Pipeline Momentum Balanced By Talc And Orthopedics Uncertainty
Analysts have nudged their average price target on Johnson & Johnson higher by about $5 per share, reflecting updated views on the company’s pharmaceutical pipeline, including stronger expectations around Tremfya and other near term therapies such as Tecvayli, Inlexzo and Darzalex treatment duration. Analyst Commentary Recent Street research on Johnson & Johnson has centered on how the pharma pipeline feeds into valuation, with analysts updating targets around specific products rather than broad macro calls.Aggiornamento della narrazione • Feb 25
JNJ: Oncology Pipeline Sale Plans And Talc Cases Will Shape Future Risk
The analyst price target for Johnson & Johnson has been raised by $1 to $232.50, as analysts factor in slightly higher revenue growth expectations, a modest adjustment to profit margin assumptions, and an updated future P/E of 25.94 following a series of recent target increases and an upgrade from major firms. Analyst Commentary Recent Street research on Johnson & Johnson has leaned positive, with several firms lifting price targets and one issuing an upgrade, while a smaller group of voices remains more cautious on how much upside is already reflected in the valuation.Aggiornamento della narrazione • Feb 10
JNJ: Oncology Pipeline And Talc Litigation Will Shape Future Risk Balance
Analysts have lifted their Johnson & Johnson fair value estimate by about US$7 to roughly US$231, reflecting research that points to slightly higher assumed revenue growth, modestly stronger profit margins, and a marginally higher future P/E multiple following a series of recent price target increases and an upgrade from several firms. Analyst Commentary Recent Street research on Johnson & Johnson has leaned more positive, with several firms adjusting price targets higher and one new initiation that frames the shares as a preferred large cap pharmaceutical name.Aggiornamento della narrazione • Jan 27
JNJ: Oncology Pipeline And Talc Litigation Will Shape Future Balanced Risk Reward
Analysts have raised their Johnson & Johnson fair value estimate by about US$13 to roughly US$224. This reflects slightly higher modeled revenue growth, a marginally higher future P/E, and supportive Street research that includes multiple recent price target increases from major firms across the sector.
Nuova narrazione • Jan 25
Broad MedTech And Complex Therapy Platforms Will Define A Stronger Future Trajectory
Catalysts About Johnson & Johnson Johnson & Johnson is a global health care company that develops and sells pharmaceuticals and medical devices across Oncology, Immunology, Neuroscience, Cardiovascular, Surgery and Vision. What are the underlying business or industry changes driving this perspective?Aggiornamento della narrazione • Jan 09
JNJ: Ortho Separation And Talc Risks Will Shape Balanced Forward Risk Reward
Analysts have nudged their fair value estimate for Johnson & Johnson slightly higher to about US$211 per share, reflecting updated views on revenue growth, profitability, and future P/E assumptions informed by recent price target increases and supportive research commentary on the company's pipeline and planned ortho separation. Analyst Commentary Recent Street research on Johnson & Johnson points to a mix of optimism around the pipeline, margin profile, and planned ortho separation, alongside ongoing attention to litigation and product risk.Aggiornamento della narrazione • Dec 19
JNJ Future Portfolio Separation And Litigation Resolution Will Shape Balanced Risk Reward Outlook
Analysts have raised their average price target on Johnson & Johnson by about $7 to roughly $209, reflecting slightly faster expected revenue growth, a modestly higher future earnings multiple, and confidence that portfolio reshaping and pipeline execution can offset near term margin pressure. Analyst Commentary Street research on Johnson & Johnson has turned incrementally more constructive, with multiple firms lifting price targets in response to stronger fundamentals and portfolio actions that are viewed as supportive of a faster growth profile.Aggiornamento della narrazione • Dec 05
JNJ: Future Reorganization And Litigation Outcomes Will Shape Risk Reward Balance
The analyst price target for Johnson & Johnson has been nudged higher, with fair value rising from approximately $200.82 to $202.54 per share, as analysts highlight slightly stronger long term revenue growth, modestly higher profit margins, and a richer future P/E multiple supported by an improving innovation pipeline and portfolio reshaping efforts. Analyst Commentary Recent research updates reflect a broadly constructive stance on Johnson & Johnson, with a growing number of firms highlighting improving fundamentals, a stronger growth profile, and a more compelling risk reward setup following the latest results and guidance.Aggiornamento della narrazione • Nov 21
JNJ: Upcoming Business Reorganization and Legal Risks Will Influence Future Performance
Johnson & Johnson's analyst price target has increased slightly from $199.56 to $200.82, as analysts cite stronger-than-expected sector performance and a constructive long-term industry outlook, which support the adjustment. Analyst Commentary Recent analyst commentary on Johnson & Johnson highlights a variety of perspectives related to the company's valuation, strategic direction, and future growth potential.Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Utili della società |
|---|---|---|---|
| Mar 29 2026 | n/a | n/a | US$21b |
| Dec 28 2025 | US$33m | US$2m | US$27b |
| Sep 28 2025 | n/a | n/a | US$25b |
| Jun 29 2025 | n/a | n/a | US$23b |
| Mar 30 2025 | n/a | n/a | US$22b |
| Dec 29 2024 | US$24m | US$2m | US$14b |
| Sep 29 2024 | n/a | n/a | US$15b |
| Jun 30 2024 | n/a | n/a | US$16b |
| Mar 31 2024 | n/a | n/a | US$17b |
| Dec 31 2023 | US$28m | US$2m | US$13b |
| Oct 01 2023 | n/a | n/a | US$12b |
| Jul 02 2023 | n/a | n/a | US$12b |
| Apr 02 2023 | n/a | n/a | US$11b |
| Jan 01 2023 | US$13m | US$1m | US$16b |
| Oct 02 2022 | n/a | n/a | US$18b |
| Jul 03 2022 | n/a | n/a | US$17b |
| Apr 03 2022 | n/a | n/a | US$20b |
| Jan 02 2022 | US$14m | US$1m | US$18b |
| Oct 03 2021 | n/a | n/a | US$18b |
| Jul 04 2021 | n/a | n/a | US$18b |
| Apr 04 2021 | n/a | n/a | US$15b |
| Jan 03 2021 | n/a | n/a | US$15b |
| Sep 27 2020 | n/a | n/a | US$17b |
| Jun 28 2020 | n/a | n/a | US$15b |
| Mar 29 2020 | n/a | n/a | US$17b |
| Dec 29 2019 | US$13m | US$970k | US$15b |
Compensazione vs Mercato: La retribuzione totale di Joaquin ($USD 32.76M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 14.65M ).
Compensazione vs guadagni: La retribuzione di Joaquin è aumentata di oltre il 20%, mentre gli utili aziendali sono diminuiti di oltre il 20% nell'ultimo anno.
AMMINISTRATORE DELEGATO
Joaquin Duato (63 yo)
4.4yrs
Mandato
US$32,758,111
Compensazione
Mr. Joaquin Duato serves as Chief Executive Officer & Director of Johnson & Johnson since January 3, 2022 and serves as its Chairman since January 02, 2023. He served as Worldwide Chairman of Pharmaceutica...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| CEO & Chairman | 4.4yrs | US$32.76m | 0.015% $ 85.8m | |
| Executive VP & CFO | 7.9yrs | US$14.41m | 0.0035% $ 20.5m | |
| Executive VP & Worldwide Chairman of Innovative Medicine | 14.4yrs | US$14.03m | 0.0081% $ 46.8m | |
| Executive Vice President of Innovative Medicine and R&D | 3.2yrs | US$12.21m | 0.0010% $ 6.0m | |
| Executive VP & Worldwide Chairman of MedTech | 2.7yrs | US$9.34m | 0.0011% $ 6.3m | |
| Controller & Chief Accounting Officer | 6.5yrs | Nessun dato | 0.0010% $ 5.9m | |
| Executive VP & Chief Information Officer | 6.6yrs | Nessun dato | 0.0011% $ 6.2m | |
| Chief Compliance Officer | no data | Nessun dato | Nessun dato | |
| Executive VP & Chief Legal Officer | 3.7yrs | Nessun dato | 0.00098% $ 5.7m | |
| Executive VP & Chief Human Resources Officer | no data | Nessun dato | 0.00082% $ 4.8m | |
| Group Chairman of MD&D Business - EMEA | no data | Nessun dato | Nessun dato | |
| Executive VP and Chief Technical Operations & Risk Officer | 7.9yrs | Nessun dato | 0.0048% $ 27.6m |
6.5yrs
Durata media
59.5yo
Età media
Gestione esperta: Il team dirigenziale di JNJ è esperto e expertise (durata media dell'incarico 6.5 anni).
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| CEO & Chairman | 4.4yrs | US$32.76m | 0.015% $ 85.8m | |
| Director | less than a year | US$59.13k | 0.000080% $ 463.9k | |
| Independent Director | 6.5yrs | US$367.55k | 0.00021% $ 1.2m | |
| Lead Independent Director | 7.2yrs | US$413.00k | 0.00012% $ 695.8k | |
| Independent Director | 3.3yrs | US$344.00k | 0.000010% $ 58.0k | |
| Independent Director | 12.7yrs | US$330.00k | 0% $ 0 | |
| Independent Director | 11yrs | US$375.00k | 0% $ 0 | |
| Independent Director | 8.2yrs | US$370.00k | 0% $ 0 | |
| Independent Director | 2.6yrs | US$347.16k | 0.000010% $ 58.0k | |
| Independent Director | 6.5yrs | US$355.00k | 0.000040% $ 231.9k | |
| Director | less than a year | US$62.50k | Nessun dato | |
| Independent Director | 5.5yrs | US$350.00k | 0% $ 0 |
6.0yrs
Durata media
63.5yo
Età media
Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di JNJ sono considerati esperti (durata media dell'incarico 6 anni).
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/06/14 04:04 |
| Prezzo dell'azione a fine giornata | 2026/06/12 00:00 |
| Utili | 2026/03/29 |
| Utili annuali | 2025/12/28 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Johnson & Johnson è coperta da 53 analisti. 23 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| David Toung | Argus Research Company |
| Matthew Miksic | Barclays |
| Lee Hambright | Bernstein |